Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC / CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

PRIME Care Study

  PRIME Care Logo  


The purpose of this study is to determine the effectiveness of providing depressed Veterans and their providers the results of pharmacogenetic (PGx) testing for psychotropic medications. The study focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of disability and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the health care of Veterans. Veteran recruitment will take place at many VA sites

Introduction to Pharmacogenetics: PRIME Care Study: https://youtu.be/X5atvMqPAUY
This whiteboard video briefly explains pharmacogenetics, what it is, and how it is being used in health care today. The role of pharmacogenetics in the VA PRIME Care study is described.
Running time: 2:59
Intended Audience: Patients and Providers


To find out which VA Medical Centers are participating in this study and the local contact information for each, click here.

ClinicalTrials.gov ID: NCT03170362